Application of Continuous Renal Replacement Therapy: What Should We Consider Based on Existing Evidence?

被引:22
|
作者
Hanafusa, Norio [1 ]
机构
[1] Tokyo Univ Hosp, Div Total Renal Care Med, Tokyo 1138655, Japan
关键词
Acute kidney injury; Continuous renal replacement therapy; Indication; Prescriptions; CRITICALLY-ILL PATIENTS; ACUTE KIDNEY INJURY; CONTINUOUS VENOVENOUS HEMOFILTRATION; EXTENDED DAILY DIALYSIS; RANDOMIZED CLINICAL-TRIAL; CONTINUOUS HEMODIAFILTRATION; INTERMITTENT HEMODIALYSIS; SEPTIC PATIENTS; HEPARIN ANTICOAGULATION; NAFAMOSTAT MESILATE;
D O I
10.1159/000441579
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Continuous renal replacement therapy (CRRT) is performed mainly in patients with acute kidney injury, severe sepsis, or septic shock. Evidence has emerged about the indications for and therapeutic conditions of CRRT. In this review, we focus on the evidence for CRRT to date. Summary: CRRT employs diffusion, convection and adsorption to remove solutes from plasma. Indications can be divided into renal and non-renal indications. Concrete renal indications have not yet been determined, except for life-threatening absolute indications. Modality selection is a point of debate. Intermittent renal replacement therapy is reportedly equivalent to CRRT in terms of overall survival. However, the selection of modality must consider individual circumstances. The optimal dosage of CRRT has proven to be lower than that previously recommended, and the dosage is almost the same as the one employed in the 'real-world' setting. Patients treated by CRRT often have bleeding complications. In this situation, regional citrate anticoagulation can be used, but nafamostat is widely used in Japan. The right jugular vein is the most preferred vascular access site because it has the lowest likelihood of catheter malfunction. As for the complications of CRRT, hypophosphatemia and nutrient loss should be managed properly. When CRRT is no longer necessary, we should consider the appropriate timing of discontinuation. Key Messages: Even though CRRT is an established technique, several points remain under debate. Individualization of therapy should be considered in light of the changes in patient characteristics. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:312 / 319
页数:8
相关论文
共 50 条
  • [1] Medical therapy for BPH: What factors should we consider?
    Rigatti, Patrizio
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (20) : 989 - 990
  • [2] Continuous renal replacement therapy: Opinions and evidence
    Ronco, C
    Bellomo, R
    Kellum, JA
    [J]. ADVANCES IN RENAL REPLACEMENT THERAPY, 2002, 9 (04): : 229 - 244
  • [3] CONTINUOUS RENAL REPLACEMENT THERAPY: WHAT HAVE WE LEARNED AND WHAT ARE KEY MILESTONES FOR THE YEARS TO COME?
    Galindo, Pablo
    Neyra, Javier A.
    [J]. REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2023, 75 (06): : 348 - 358
  • [4] ACUTE RENAL FAILURE IN SEPTIC SHOCK. SHOULD WE CONSIDER DIFFERENT CONTINUOUS RENAL REPLACEMENT THERAPIES ON EACH RIFLE SCORE STAGE?
    Sabater, J.
    Perez, X. L.
    Albertos, R.
    Gutierrez, D.
    Labad, X.
    [J]. INTENSIVE CARE MEDICINE, 2009, 35 : 239 - 239
  • [5] Prevention of childhood obesity - what type of evidence should we consider relevant?
    Doak, C.
    Heitmann, B. L.
    Summerbell, C.
    Lissner, L.
    [J]. OBESITY REVIEWS, 2009, 10 (03) : 350 - 356
  • [6] Renal replacement therapy in the ICU: when should we STARRT?
    Bellomo, Rinaldo
    [J]. CRITICAL CARE AND RESUSCITATION, 2019, 21 (03) : 156 - 157
  • [7] Continuous Renal Replacement Therapy and Anticoagulation: What Are the Options?
    Dirkes, Susan
    Wonnacott, Rob
    [J]. CRITICAL CARE NURSE, 2016, 36 (02) : 34 - 41
  • [8] Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?
    H. M. Oudemans-van Straaten
    J. P. J. Wester
    A. C. J. M. de Pont
    M. R. C. Schetz
    [J]. Intensive Care Medicine, 2006, 32 : 188 - 202
  • [9] Continuous renal replacement therapy: are we getting the dose right?
    S Martin
    M Al-Haddad
    [J]. Critical Care, 14 (Suppl 1):
  • [10] Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?
    Oudemans-van Straaten, HM
    Wester, JPJ
    de Pont, ACJM
    Schetz, MRC
    [J]. INTENSIVE CARE MEDICINE, 2006, 32 (02) : 188 - 202